started · updated
European Union adopts major pharmaceutical legislation reform
The Council of the European Union has adopted a major pharmaceutical reform package, marking the most significant update to EU drug laws in over two decades. The legislation aims to ensure equitable access to safe, effective, and affordable medicines while strengthening the competitiveness of the European pharmaceutical sector.
Key provisions include a standardized eight-year data protection period for new medicines, with the possibility of extending market protection for up to eleven years if specific criteria are met, such as addressing unmet medical needs or conducting comparative clinical trials. The reform also introduces incentives for developing priority antibiotics to combat antimicrobial resistance.
To prevent supply shortages, EU member states will gain the authority to require pharmaceutical companies to provide sufficient quantities of essential medicines. Additionally, the reform seeks to reduce bureaucracy by shortening the European Medicines Agency’s review timelines from 210 to 180 days and introducing electronic patient leaflets.
Entities
Carsten Linnemann · Council of the European Union · European Medicines Agency · European Parliament · European Union · European Union · Jennifer Carroll MacNeill
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] The legislation seeks to boost industry competitiveness by reducing regulatory burdens. www.cmjornal.pt · www.pressclub.be · www.upday.com
- [● 2 SOURCES] Market protection for new medicines can be extended by one year for products meeting specific innovation criteria. www.pressclub.be · www.upday.com
- [● 4 SOURCES] The Council of the European Union adopted a new set of rules to reform pharmaceutical legislation. www.cmjornal.pt · www.pressclub.be · live.handelsblatt.com · www.upday.com
- [● 3 SOURCES] Companies introducing a new medicine will benefit from an eight-year data protection period. www.cmjornal.pt · www.pressclub.be · www.upday.com
- [○ 1 SOURCE] EU member states will have the power to require pharmaceutical companies to provide sufficient quantities of essential medicines. www.cmjornal.pt
- [● 3 SOURCES] The reform aims to ensure equitable access to safe, effective, and affordable medicines across the EU. www.cmjornal.pt · www.pressclub.be · www.upday.com
- [● 2 SOURCES] The total combined period of protection for a new medicinal product cannot exceed eleven years. www.pressclub.be · www.upday.com
- [○ 1 SOURCE] The package includes incentives for developing priority antibiotics to combat antimicrobial resistance. www.cmjornal.pt